Geron/$GERN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Geron
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
- Ticker
- $GERN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 258
- Headquarters
- Foster City, United States
- Website
- www.geron.com
Geron Metrics
BasicAdvanced
$739M
-
-$0.10
0.61
-
Price and volume
Market cap
$739M
Beta
0.61
52-week high
$2.01
52-week low
$1.04
Average daily volume
8.4M
Financial strength
Current ratio
6.915
Quick ratio
4.304
Long term debt to equity
0.554
Total debt to equity
0.559
Interest coverage (TTM)
-1.17%
Profitability
EBITDA (TTM)
-34.799
Gross margin (TTM)
58.50%
Net profit margin (TTM)
-33.05%
Operating margin (TTM)
-17.25%
Revenue per employee (TTM)
$790,000
Management effectiveness
Return on assets (TTM)
-4.11%
Return on equity (TTM)
-28.28%
Valuation
Price to revenue (TTM)
3.759
Price to book
3.38
Price to tangible book (TTM)
3.38
Price to free cash flow (TTM)
-6.7
Free cash flow yield (TTM)
-14.92%
Free cash flow per share (TTM)
-0.172
Growth
Revenue change (TTM)
24.39%
Earnings per share change (TTM)
-23.63%
3-year revenue growth (CAGR)
668.90%
10-year revenue growth (CAGR)
18.80%
3-year earnings per share growth (CAGR)
-34.58%
10-year earnings per share growth (CAGR)
29.57%
What the Analysts think about Geron
Analyst ratings (Buy, Hold, Sell) for Geron stock.
Analyst projections of the future price of Geron stock.
Bulls say / Bears say
RYTELO sales are growing: Q2 2026 net revenue rose 17% year on year to $57.5 million, with demand up 5% on the previous quarter and ordering accounts expanding. Geron reiterated full-year revenue guidance of $220 million to $240 million. (Geron)
A real-world study in 40 heavily treated patients with lower-risk MDS found that 37.5% achieved transfusion independence for at least eight weeks, with a safety profile generally consistent with prior findings. This evidence may help build confidence in RYTELO beyond its clinical-trial population. (Geron)
RYTELO has an opportunity to reach eligible patients outside the US: it has European Commission authorisation, and Geron says it is preparing a selective EU commercial strategy. Successful launches could add sales beyond its current US business. (SEC)
Geron discontinued its Phase 3 IMpactMF trial after the independent monitoring committee concluded it was unlikely to meet its overall-survival endpoint. This removes a major potential growth opportunity for imetelstat in relapsed or refractory myelofibrosis. (Geron)
RYTELO can cause severe drops in platelet and neutrophil counts: the company reports Grade 3 or 4 events in 65% and 72% of treated patients, respectively. These risks require close blood-count monitoring and may complicate treatment for patients and clinicians. (Geron)
Geron remains dependent on RYTELO as its only approved product, while its 2026 revenue guidance is broadly comparable with expected operating expenses. The company also carries term-loan debt and a sales-based royalty obligation, leaving limited room for execution setbacks to be absorbed without affecting its finances. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Geron Financial Performance
Revenues and expenses
Geron Earnings Performance
Company profitability
Upcoming events
No upcoming events
Geron News
AllArticlesVideos
Geron discontinues late-stage trial of blood cancer drug
Reuters2 days ago
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Business Wire3 weeks ago
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
MarketBeat1 month ago
Funds containing Geron
Fund name | Fund size | $GERN weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.05% |
iShares Ageing Population£AGES | $953M | 0.05% |
iShares Ageing Population€AGED | $903M | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.